Skip to main content
SpringerLink
Log in

Eluxadoline: do not use in patients without a gallbladder

  • News item
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • US Food and Drug Administration. FDA Drug Safety Communication: FDA warns about increased risk of serious pancreatitis with irritable bowel drug Viberzi (eluxadoline) in patients without a gallbladder. Internet Document : 15 Mar 2017. Available from: URL: https://www.fda.gov/Drugs/DrugSafety/ucm546154.htm

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Eluxadoline: do not use in patients without a gallbladder. Reactions Weekly 1645, 2 (2017). https://doi.org/10.1007/s40278-017-28084-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-017-28084-x

Search

Navigation